Education
About Us
Working with TipRanks
Follow Us
Evogene Ltd. (EVGN)
:EVGN
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.61Last Year’s EPS
-1.06Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 21, 2025
|% Change Since: -14.17%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted Evogene's strategic efforts to reduce expenses and successfully execute acquisitions, leading to a more sustainable financial position. However, it also revealed a significant revenue decline and the need for additional funding for certain projects, balancing out the positive achievements.Company Guidance
During the first quarter of 2025, Evogene reported total revenues of approximately $2.4 million, a decrease from $4.2 million in the same period in 2024. This decline was primarily due to the previous year's inclusion of significant license fee payments. The primary revenue driver in 2025 was an increase in seed sales by Casterra. The company implemented an expense reduction plan, reflected in reduced operating expenses of approximately $5 million compared to $8 million in 2024. R&D expenses were reduced to $3.2 million from $4.8 million, and sales and marketing expenses decreased to $645,000 from $1 million. As of the end of the first quarter, cash and short-term bank deposits were approximately $9.8 million. Evogene also highlighted a transaction with ICL, expected to close in the second quarter, involving the acquisition of Lavie Bio's assets, valued at $15.25 million, and the MicroBoost AI for Ag tech-engine for $3.5 million.Expense Reduction Plan
Evogene has established an expense reduction plan reflected in the first-quarter results and expects it to be completed by the second quarter of 2025. This plan led to a decrease in total operating expenses from $8 million in Q1 2024 to $5 million in Q1 2025.
Successful Acquisition of Lavie Bio by ICL
Evogene announced the acquisition of Lavie Bio's activities by ICL for $15.25 million, plus $3.5 million for the MicroBoost AI tech-engine. The deal is expected to close in the second quarter of 2025.
Casterra's Seed Sales Growth
Casterra delivered 250 tons of castor seeds in Q1 2025, surpassing the 215 tons delivered in the entire year of 2024, indicating strong growth in this segment.
AgPlenus' New Fungicide Discovery
AgPlenus discovered a new mode of action for fungicides against Septoria in wheat, with plans to engage licensing partners by year-end.
Advancements in ChemPass-AI for Pharma
Evogene has made substantial progress in refining ChemPass-AI for pharma, particularly in its collaboration with Google Cloud to develop a foundation model application.
EVGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
EVGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 21, 2025 | $1.27 | $1.18 | -7.09% |
Mar 06, 2025 | $1.41 | $1.41 | 0.00% |
Nov 21, 2024 | $1.65 | $1.60 | -3.03% |
Aug 22, 2024 | $3.98 | $3.55 | -10.80% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Evogene Ltd. (EVGN) report earnings?
Evogene Ltd. (EVGN) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Evogene Ltd. (EVGN) earnings time?
Evogene Ltd. (EVGN) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EVGN EPS forecast?
EVGN EPS forecast for the fiscal quarter 2025 (Q2) is -0.61.